Appendix cancer secondary prevention

Appendix cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Differentiating Appendix cancer from other Diseases
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
MRI
CT scan
Echocardiography and Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Appendix cancer secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Appendix cancer secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Appendix cancer secondary prevention
CDC on Appendix cancer secondary prevention
Appendix cancer secondary prevention in the news
Blogs on Appendix cancer secondary prevention
Directions to Hospitals Treating Appendix cancer
Risk calculators and risk factors for Appendix cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

There are neither evidence based guidelines nor RCTs for follow up of appendix carcinoid tumors. Meanwhile, consensus based effective measures for the secondary prevention of appendix cancer include follow up history and physical examination, tumor marker measurements like CEA, CA 125, CA 19-9, follow up imaging studies, carcinoid tumor markers such serotonin, and specific imaging studies such as octreotide scintigraphy.

Secondary Prevention

Effective measures for the secondary prevention of appendix cancer include:

• Cartcinoid tumors of appendix:

• National Comprehensive Cancer Network (NCCN) and North American Neuroendocrine Tumor Society (NANETS) recommendations are base on the tumor size

• Less than 2 cm : No follow up

• NANETS devided tumors < 2 cm into two categories:

• Tumors less than 1 cm needs no further follow up
• Tumors between 1 and 2 cm with nodal metastasis, vascular invasion, lymphatic metastasis, mesoappendical invasion, intermediate and high grade as well as mixed histology): the same as tumors larger than 2 cm<math>\blacktriangledown</math>

• 2 cm and more: History an d Physical Examination between 3-12 months plus tumor markers as well as imaging studies consideration for the first year, then tumor markers every 6-12 months (5HIAA and Chromogranin), imaging as clinically indicated.
• Followup Imaging studies: 6 moth after surgery, every 6-12 months for at least 7 years.

• Metastatic disease palliative managements:

• Liver resection for selected patients

• Embolization of the hepatic artery

• Somatostatin analogs did not show to reduce the tumor size, but they are helpful in symptom control

• Adenocarcinoma
• There no appropriate evidences in role tumor markers for followup of the patients with appendix adenocrcinoma, indeed current consensus is based on colorectal cancer experience.

• CEA, CA 125, CA 19-9 every 6 month for the first two years, then yearly for at least 3 more years, plus continued follow up in selected cases.
• Followup Imaging studies: 6 moth after surgery, every 6-12 months for at least 7 years